Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature

[1]  R. Millikan,et al.  Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. , 2014, The Journal of urology.

[2]  F. Montorsi,et al.  Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients , 2017, Clinical genitourinary cancer.

[3]  K. Shimada,et al.  Integrative Assessment of Pretreatment Inflammation-, Nutrition-, and Muscle-Based Prognostic Markers in Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy , 2017, Oncology.

[4]  T. Guzzo,et al.  Preoperative Anemia and Low Hemoglobin Level Are Associated With Worse Clinical Outcomes in Patients With Bladder Cancer Undergoing Radical Cystectomy: A Meta‐Analysis , 2017, Clinical genitourinary cancer.

[5]  F. Montorsi,et al.  The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. , 2017, Urologic oncology.

[6]  J. Witjes,et al.  MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER , 2016 .

[7]  M. Sibony,et al.  Impact of body mass index on the oncological outcomes of patients treated with radical cystectomy for muscle-invasive bladder cancer , 2017, World Journal of Urology.

[8]  A. Briganti,et al.  Lymphocyte‐to‐monocyte ratio and neutrophil‐to‐lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy , 2017, Journal of surgical oncology.

[9]  T. Klatte,et al.  Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy , 2016, Clinical genitourinary cancer.

[10]  F. Zhou,et al.  The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy. , 2016, Urologic oncology.

[11]  M. Milowsky,et al.  Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Pow-Sang,et al.  Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation. , 2016, Clinical genitourinary cancer.

[13]  F. Montorsi,et al.  A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy , 2016, World Journal of Urology.

[14]  G. Muto,et al.  Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy , 2015, World journal of urology.

[15]  S. Shariat,et al.  The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy , 2015, World Journal of Urology.

[16]  R. Thompson,et al.  Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. , 2014, European urology.

[17]  F. Saad,et al.  Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer , 2014, World Journal of Urology.

[18]  D. Mukherji,et al.  Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis , 2014, BMC Urology.

[19]  W. Otto,et al.  The Charlson Comorbidity Index Predicts Survival after Disease Recurrence in Patients following Radical Cystectomy for Urothelial Carcinoma of the Bladder , 2014, Urologia Internationalis.

[20]  U. Capitanio,et al.  Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma. , 2014, Anticancer research.

[21]  S. Daneshmand,et al.  The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer , 2014, BJU international.

[22]  Y. Lotan,et al.  Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. , 2014, Urology.

[23]  S. Daneshmand,et al.  Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy. , 2014, Urologic oncology.

[24]  M. Babjuk,et al.  Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. , 2013, European urology.

[25]  Anirban P. Mitra,et al.  Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades , 2013, BJU international.

[26]  J. Patard,et al.  Positive surgical margins and their locations in specimens are adverse prognosis features after radical cystectomy in non‐metastatic carcinoma invading bladder muscle: results from a nationwide case–control study , 2013, BJU international.

[27]  David A. Green,et al.  Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. , 2013, European journal of cancer.

[28]  M. Babjuk,et al.  Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy , 2013, BJU international.

[29]  Choung-Soo Kim,et al.  Smoking and survival after radical cystectomy for bladder cancer. , 2012, Urology.

[30]  G. Muto,et al.  Development and external validation of lymph node density cut‐off points in prospective series of radical cystectomy and pelvic lymph node dissection , 2012, International journal of urology : official journal of the Japanese Urological Association.

[31]  A. Zlotta,et al.  Does patient age affect survival after radical cystectomy? , 2012, BJU international.

[32]  David A. Green,et al.  Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling , 2012, British Journal of Cancer.

[33]  D. Sjoberg,et al.  Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. , 2012, European urology.

[34]  K. Bensalah,et al.  Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. , 2012, Urologic oncology.

[35]  T. H. van der Kwast,et al.  Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer , 2012, BJU international.

[36]  F. Burkhard,et al.  Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. , 2011, The Journal of urology.

[37]  F. Montorsi,et al.  Concomitant Carcinoma in situ in Cystectomy Specimens Is Not Associated with Clinical Outcomes after Surgery , 2011, Urologia Internationalis.

[38]  K. Bensalah,et al.  Oncologic Outcomes and Survival in pT0 Tumors After Radical Cystectomy in Patients Without Neoadjuvant Chemotherapy: Results from a Large Multicentre Collaborative Study , 2011, Annals of Surgical Oncology.

[39]  C. Stief,et al.  Association Between the Number of Dissected Lymph Nodes During Pelvic Lymphadenectomy and Cancer-Specific Survival in Patients with Lymph Node–Negative Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy , 2011, Annals of Surgical Oncology.

[40]  I. Frank,et al.  Multifactorial, site‐specific recurrence model after radical cystectomy for urothelial carcinoma , 2010, Cancer.

[41]  D. Penson,et al.  Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. , 2009, The Journal of urology.

[42]  C. Luke,et al.  Bladder cancer survivals in New South Wales, Australia: why do women have poorer survival than men? , 2009, BJU international.

[43]  A. Vickers,et al.  Age‐adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer , 2008, Cancer.

[44]  K. Kavanagh,et al.  Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. , 2007, The Journal of urology.

[45]  Y. Lotan,et al.  Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. , 2007, European urology.

[46]  Y. Lotan,et al.  Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. , 2007, European urology.

[47]  Y. Lotan,et al.  Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. , 2006, Urology.

[48]  Michael W Kattan,et al.  Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Y. Lotan,et al.  Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Yair Lotan,et al.  Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause-Specific Survival, and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cystectomy , 2005 .

[51]  John T. Wei,et al.  The effects of stage divergence on survival after radical cystectomy for urothelial cancer. , 2005, Urologic oncology.

[52]  Sam S. Chang,et al.  Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. , 2004, The Journal of urology.

[53]  F. Song,et al.  Evaluating non-randomised intervention studies. , 2003, Health technology assessment.

[54]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[55]  H. G. van der Poel,et al.  Gender differences in stage distribution of bladder cancer. , 2000, Urology.

[56]  M. Gleave,et al.  Balancing risk and benefit of extended pelvic lymph node dissection in patients undergoing radical cystectomy , 2015, World Journal of Urology.

[57]  G. Sauter,et al.  Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy? , 2015, Urologic oncology.

[58]  M. Babjuk,et al.  Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. , 2014, Urologic oncology.

[59]  Anirban P. Mitra,et al.  Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients. , 2014, Urologic oncology.

[60]  F. Montorsi,et al.  Development and Validation of a Reference Table for Prediction of Postoperative Mortality Rate in Patients Treated with Radical Cystectomy: A Population-based Study , 2011, Annals of Surgical Oncology.

[61]  A. Kibel.  International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial , 2011 .